Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: PR Newswire
The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Juvenile Idiopathic Arthritis Market SummaryAccording to DelveInsight's analysis, the market size for juvenile idiopathic arthritis was found to be USD 2.3 billion in the
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsightPR Newswire
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple MyelomaBusiness Wire
- Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth [Yahoo! Finance]Yahoo! Finance
- The top-performing pharma and biotech stocks as group sees resurgence [Seeking Alpha]Seeking Alpha
- Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline Outlook - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 2/11/26 - Form 10-K
- 2/5/26 - Form 8-K
- 2/3/26 - Form 4
- BMY's page on the SEC website